FDA Approves GABAPENTIN — STALLION LABORATORIES PRIVATE LIMITED

Following the FDA’s August 7 approval of generic Gabapentin, Stallion Laboratories Private Limited adds a new player to a crowded and highly competitive market, potentially intensifying price pressure on this widely prescribed neurologic drug. This launch may create significant competition for branded generics, potentially impacting pricing strategies and market share within the oral Gabapentin segment shortly after the approval.